TCRX

Over the past six months, TScan Therapeutics' stock has been influenced by several events. These include reporting Q1 revenue of $982,000, which fell short of the anticipated $2.5 million, reporting first-quarter 2026 financial results and providing a corporate update, acceptance of an upcoming presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting, participation in the 25th Annual Needham Virtual Healthcare Conference and the TD Cowen 46th Annual Health Care Conference, completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial and announcement FDA clearance of Investigational New Drug (IND) applications for heme candidates TSC-102-A01 and TSC-102-A03, holding an ASH 2025 Virtual KOL Event, announcing positive updated data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition, and meeting with the FDA to discuss a pivotal trial design for TSC-101. The stock price has fluctuated between $0.88 and $2.57, with a share price of $1.25 as of May 6, 2026.